IPO de Lisboa; Servico de Pneumologia
About IPO de Lisboa; Servico de Pneumologia
The Instituto Português de Oncologia Francisco Gentil, also known as the Instituto Português de Oncologia, Portuguese for Portuguese Oncology Institute, is a state-run cancer hospital and research organization in Portugal. The I.P.O. has autonomous regional branches in Lisbon, Porto and Coimbra.
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
3
Clinical Trials at IPO de Lisboa; Servico de Pneumologia
During the past decade, IPO de Lisboa; Servico de Pneumologia conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 3 clinical trials were completed, i.e. on
average, 300% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutations
2011-03-31
2017-09-29
Completed
30
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants
2014-08-19
2026-09-29
Active, not recruiting
303
A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]
2015-06-11
2021-02-17
Completed
1,021
Clinical Trials Sponsors and Collaborators
Clinical Trials Conditions at IPO de Lisboa; Servico de Pneumologia
According to Clinical.Site data, the most researched conditions in "IPO de Lisboa; Servico de Pneumologia" are
"Non-Small Cell Lung Cancer" (1 trials), "Non-Squamous Non-Small Cell Lung Cancer" (1 trials) and "Squamous Non-Small Cell Lung Cancer" (1 trials). Many other conditions were trialed in "IPO de Lisboa; Servico de Pneumologia" in a lesser frequency.
Clinical Trials Intervention Types at IPO de Lisboa; Servico de Pneumologia
Most popular intervention types in "IPO de Lisboa; Servico de Pneumologia" are "Drug" (3 trials). Other intervention types were less common.
The name of intervention was led by "Alectinib" (1 trials), "Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody" (1 trials), "Carboplatin" (1 trials), "Crizotinib" (1 trials) and "Erlotinib" (1 trials). Other intervention names were less common.
Clinical Trials Genders at IPO de Lisboa; Servico de Pneumologia
The vast majority of trials in "IPO de Lisboa; Servico de Pneumologia" are
3 trials for "All" genders.
Clinical Trials Status at IPO de Lisboa; Servico de Pneumologia
Currently, there are NaN active trials in "IPO de Lisboa; Servico de Pneumologia".
undefined are not yet recruiting,
undefined are recruiting,
1 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 2 completed trials in IPO de Lisboa; Servico de Pneumologia,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in IPO de Lisboa; Servico de Pneumologia, 0 "Phase 1"
clinical trials were conducted, 1 "Phase 2" clinical
trials and 2 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".